Skip to main content
Publications
Dubner SJ, Teutsch C, Huisman MV, Diener H-C, Halperin J, Rothman KJ , Ma C-S, Chuquiure-Valenzuela E, Bergler-Klein J, Zint K, Franca LR, Lu S, Paquette M, Lip GYH. Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF . ESC Heart Fail. 2020 Oct;7(5):2679-89. doi: 10.1002/ehf2.12857
Vaz LE, Kleinman KP, Kawai AT , Jin R, Kassler WJ, Grant PS, Rett MD, Goldmann DA, Calderwood MS, Soumerai SB, Lee GM. Impact of Medicare's Hospital-Acquired Condition policy on infections in safety net and non-safety net hospitals . Infect Control Hosp Epidemiol. 2015 Jun;36(6):649-55. doi: 10.1017/ice.2015.38.
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043